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Mechanistic Biomarkers Provide Early and Sensitive
Detection of Acetaminophen-Induced Acute Liver
Injury at First Presentation to Hospital
Daniel J. Antoine,1* James W. Dear,2,3* Philip Starkey Lewis,1* Vivien Platt,1 Judy Coyle,4 Moyra Masson,4
Ruben H. Thanacoody,5 Alasdair J. Gray,4 David J. Webb,2,3 Jonathan G. Moggs,6 D. Nicholas Bateman,2
Christopher E. Goldring,1 and B. Kevin Park1
Acetaminophen overdose is a common reason for hospital admission and the most frequent
cause of hepatotoxicity in the Western world. Early identification would facilitate patient-
individualized treatment strategies. We investigated the potential of a panel of novel bio-
markers (with enhanced liver expression or linked to the mechanisms of toxicity) to identify
patients with acetaminophen-induced acute liver injury (ALI) at first presentation to the
hospital when currently used markers are within the normal range. In the first hospital pre-
sentation plasma sample from patients (n 5 129), we measured microRNA-122 (miR-122;
high liver specificity), high mobility group box-1 (HMGB1; marker of necrosis), full-length
and caspase-cleaved keratin-18 (K18; markers of necrosis and apoptosis), and glutamate
dehydrogenase (GLDH; marker of mitochondrial dysfunction). Receiver operator character-
istic curve analysis and positive/negative predictive values were used to compare sensitivity
to report liver injury versus alanine transaminase (ALT) and International Normalized Ratio
(INR). In all patients, biomarkers at first presentation significantly correlated with peak ALT
or INR. In patients presenting with normal ALT or INR, miR-122, HMGB1, and necrosis
K18 identified the development of liver injury (n 5 15) or not (n 5 84) with a high degree
of accuracy and significantly outperformed ALT, INR, and plasma acetaminophen concen-
tration for the prediction of subsequent ALI (n 5 11) compared with no ALI (n 5 52) in
patients presenting within 8 hours of overdose. Conclusion: Elevations in plasma miR-122,
HMGB1, and necrosis K18 identified subsequent ALI development in patients on admission
to the hospital, soon after acetaminophen overdose, and in patients with ALTs in the normal
range. The application of such a biomarker panel could improve the speed of clinical deci-
sion-making, both in the treatment of ALI and the design/execution of patient-individual-
ized treatment strategies. (HEPATOLOGY 2013;58:777-787)
A
cetaminophen (paracetamol) overdose is a
common reason for hospital admission and
accounted for 38,000 emergency hospital
admissions in the financial year 2010-2011 in England
alone.1 Antidote treatment with acetylcysteine (AC)
takes at least 20 hours to complete, which results in
significant hospital bed occupancy (around 47,000 bed
days per year in England). Also, adverse reactions to
AC are common; up to 45% of treated patients de-
velop adverse effects, which includes mainly vomiting
and nausea.2 However, in a study of 362 patients,
15% experienced anaphylactoid reactions that required
cessation of AC3 and there have been incidences of
fatalities.4 Therefore, careful patient selection is
Abbreviations: AC, acetylcysteine; ALI, acute liver injury; ALT, alanine aminotransferase; HMGB1, high mobility group box-1; GLDH, glutamate
dehydrogenase; INR, International Normalized Ratio; K18, keratin-18; miRNA, microRNA; ROC, receiver operating characteristic.
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required to maximize the balance of risk to benefit.
The decision to start treatment is predominately based
on the dose of acetaminophen ingested and a timed
blood acetaminophen concentration, because the ma-
jority of patients present to the hospital soon after
drug ingestion, before acute liver injury (ALI) can be
diagnosed, or confidently excluded, using current
blood-based biomarkers such as alanine aminotransa-
minase (ALT). This early clinical uncertainty regarding
the presence of liver cell injury prevents treatment
being individualized, potentially leading to patients
being overtreated with a time-consuming and poten-
tially harmful antidote or undertreated, with increased
risk of ALI.
New biomarkers or panels of biomarkers that report
acetaminophen-induced ALI at the earliest possible
timepoint are required. Moreover, their potential to
provide insight into the underlying mechanistic basis
of ALI is increasingly recognized as fundamental to
efforts in translational research and patient treatment
stratification.5 Such biomarkers could permit therapy
to be targeted to patients at high risk of adverse out-
come or allow the early and safe discharge of well/low-
risk groups.
Recent preclinical reports, from our group and else-
where, of acetaminophen-induced ALI have identified
microRNA-122 (miR-122), high mobility group box-1
(HMGB1), keratin-18 (K18, both caspase-cleaved and
full-length), and glutamate dehydrogenase (GLDH) as
sensitive markers of hepatotoxicity.6-8 These blood-
based biomarkers have been applied to the clinical set-
ting of severe acetaminophen hepatotoxicity in patient
cohorts from both the UK and USA and some have
been reported to more accurately predict patient prog-
nosis and outcome than currently used clinical chemis-
try parameters; in particular, the acetylated isoform of
HMGB1 has been shown to provide superior prognos-
tic potential than ALT activity.8-10
In addition to the early diagnosis of acetaminophen-
induced liver injury in rodent models, and the predic-
tion of patient prognosis once hepatotoxicity is estab-
lished, these biomarkers can provide enhanced mecha-
nistic information regarding the underlying basis of
acetaminophen poisoning. HMGB1 is reflective of cell
necrosis and activated immune cells.11 The caspase-
cleaved form of K18 has been shown to reflect cell ap-
optosis and the full-length variant, necrosis.12,13
GLDH is highly expressed in the mitochondria of the
liver and can report mitochondrial dysfunction, while
miR-122 has been shown to be an earlier marker of
acetaminophen-induced liver injury than ALT in mice
and provides enhanced hepatic specificity over current
clinical biomarkers.7,8,14 However, despite their clinical
potential, few data exist in man on the value of these
markers in reporting acetaminophen-induced liver
injury earlier than currently used approaches.
Therefore, we assessed the potential utility of miR-
122, HMGB1, K18, and GLDH to serve as early bio-
markers of acetaminophen-induced ALI. We hypothe-
sized that based on superior tissue specificity, earlier
time of release, a mechanistic association or increased
sensitivity with respect to bioanalysis, elevations in
these blood-based biomarkers could identify patients
with ALI at first presentation to the hospital emer-
gency department.
Patients and Methods
Patients. Patients (total N ¼ 129) were recruited
from the Royal Infirmary of Edinburgh, UK (N ¼
107) and the Royal Victoria Infirmary, Newcastle-
Upon-Tyne, UK (N ¼ 22). Full informed consent was
obtained; the study was approved by the local research
Ethics Committee. Inclusion criteria were: adult with a
clear history of single excess acetaminophen ingestion
and a timed blood acetaminophen concentration that
was judged by the treating physician to necessitate hos-
pital admission for intravenous AC therapy, as per UK
guidelines at the time of study (www.toxbase.org).
Exclusion criteria were: patients detained under the
Mental Health Act; patients with known permanent
cognitive impairment; patients with a life-threatening
illness; unreliable history of acetaminophen overdose;
patients who take anticoagulants therapeutically or
have taken an overdose of anticoagulants; and patients
who, in the opinion of the responsible clinician/nurse,
were unlikely to complete the full course of AC. All
patients completed the full course of AC treatment. In
all, 97 patients were participants in the Scottish and
Newcastle Antiemetic Pretreatment for Acetaminophen
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Poisoning study (SNAP, EudraCT number 2009-
017800-10), a randomized clinical trial designed to
assess if ondansetron is effective in reducing nausea
and vomiting in patients poisoned with acetaminophen
treated with AC. As a predefined part of the SNAP
trial protocol, blood samples were collected for bio-
marker evaluation. In all 129 study participants, blood
samples were collected at the time of first presentation
to the hospital, before AC (and for SNAP study partic-
ipants, ondansetron or placebo) therapy had com-
menced. Plasma was separated and the samples were
stored at 80C until analysis. For all study partici-
pants, demographic data and blood results were
recorded. ALI was defined as peak serum ALT activity
greater than 3 the upper limit of the normal range
(ULN ¼ 50 IU/L), the UK indication for continuing
AC therapy after completion of the initial regimen
(www.toxbase.org) at the time of the study. Plasma
biomarkers were determined as previously described
for miR-122,10 HMGB1,9 K18,9 and GLDH.15 For
miR-122 measurement (delta Ct), let-7d provided bio-
logical standardization. The persons measuring the bio-
markers were blinded to the biochemistry results of
the patients.
Statistical Analysis. Data are presented as median
and range or interquartile range (IQR). Each dataset
was analyzed for nonnormality using a Shapiro-Wilk
test. For two nonnormal datasets, comparisons were
made using the Mann-Whitney U test. The Kruskall-
Wallis test was used to determine significance between
more than two nonnormal sample groups. All calcula-
tions were performed using StatsDirect statistical soft-
ware. For correlative analysis, Pearson’s correlation test,
R2, and receiver operator characteristic (ROC) curve
analysis were carried out using GraphPad PRISM soft-
ware. Results were considered significant when P <
0.05. The funding sources had no influence over the
study design, data analysis, or article production.
Results
Biomarker Concentration at Hospital Presenta-
tion Correlated With Subsequent Liver Injury. In
our cohort, there were 51 men (40%) and 78 women
(60%) with a median age of 34 years (Table 1). Fifty-
four percent of this cohort had at least one risk factor
for acetaminophen-induced liver injury (at the time of
study these risk factors were considered to be: malnour-
ishment, nutritional deficiency, or being at risk of he-
patic enzyme induction, such as due to chronic alcohol
ingestion). Seventy-three percent of the total cohort had
taken one extra medication with the acetaminophen
overdose; the most common coingested drug class was
nonopioid analgesics. The median time (IQR) from
acetaminophen ingestion to first blood sample collection
was 8 hours (6-15 hours). The median admission blood
acetaminophen concentration was 120 mg/L (IQR, 63-
179). From timed plasma acetaminophen concentra-
tions, the Rumack-Matthew nomogram indicated that
all 129 patients required AC therapy. The median
(IQR) clinical chemistry values at first hospital presenta-
tion were: serum creatinine: 67 lmol/L (60-82), biliru-
bin: 5 lmol/L (7-11), serum ALT activity: 22 IU/L
(16-58), serum ALP activity: 75 IU/L (61-95), serum
GGT activity: 24 IU/L (15-46) and an International
Normalized Ratio (INR) of 1.0 (0.9-1.1). The number
of patients presenting with a serum ALT activity less
than 3 ULN was 98 (76%), with 31 (24%) patients
more than 3 ULN. The number of patients present-
ing with an INR ratio <1.5 was 107 (85%) with 19
(15%) presenting with an INR >1.5. Three patients
did not have an INR determined from the presentation
sample. No patients required liver transplantation or
developed encephalopathy.
We measured miR-122, HMGB1, apoptosis K18,
necrosis K18, and GLDH activity in plasma obtained
at the point of hospital admission, before AC treat-
ment had begun, but when a timed blood acetamino-
phen concentration had indicated the requirement for
AC therapy. We performed a correlation analysis on
values obtained from each individual marker against
the peak serum ALT activity during patient
Table 1. Clinical Parameters of the Acetaminophen Overdose
Patient Cohort
Number 129
Sex (male:female) 51:78
Age (years) 34 (24.5-47.0)
Risk Factors (% of cohort) 54
Amount of acetaminophen ingested (g) 18.0 (13.0-25.0)
Time from ingestion to first blood sample (hr) 8.0 (6.0-15.0)
Admission acetaminophen concentration (mg/L) 120.0 (63.0-179.0)
Time from ingestion to start of AC treatment (hr) 10.0 (7.0-19.0)
Admission serum creatinine (lmol/L) 67.0 (60.0-81.5)
Admission bilirubin (lmol/L) 5.0 (7.0-11.0)
Admission ALT activity (IU/L) 22.0 (16.0-57.5)
Admission ALP activity (IU/L) 75.0 (60.5-94.5)
Admission GGT activity (IU/L) 24.0 (15.0-46.0)
Admission INR 1.0 (0.9-1.1)
Number with admission ALT < ULN 98
Number with peak ALT > 3x ULN 31
Number with peak ALT > 1,000 U/L 20
Number with admission INR < 1.5 107
Number with peak INR > 1.5 19
Various clinical parameters of the patient cohort who present early after acet-
aminophen ingestion. AC, acetyl-cysteine; ALT, alanine aminotransferase; ALP,
alkaline phosphatase; GGT, gamma glutamyl transpeptidase; INR, International
Normalized Ratio; ULN, upper limit of normal.
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hospitalization. The presentation serum miR-122,
HMGB1, apoptosis K18, necrosis K18, and GLDH
activity values all significantly correlated with peak
ALT activity values (P < 0.0001, Fig. 1A-E). The cor-
relation coefficients (R2) were 0.14, 0.67, 0.57, 0.59,
and 0.45 and the Pearson R values (95% confidence
interval [CI]) were 0.37 (0.21-0.52), 0.82 (0.75-0.87),
0.75 (0.67, 0.82), 0.77 (0.69-0.83), and 0.67 (0.56-
0.76) for miR-122, HMGB1, apoptosis K18, necrosis
K18, and GLDH activity, respectively.
We performed a correlation analysis from individual
marker values at first presentation against the peak
INR value during patient hospitalization. The presen-
tation values for plasma miR-122, HMGB1, apoptosis
K18, necrosis K18, and GLDH activity all significantly
correlated with peak INR values (P < 0.0001, Fig.
2A-E). The correlation coefficients (R2) were 0.24,
0.42, 0.29, 0.34, and 0.13 and the Pearson R values
(95% CI) were 0.49 (0.34-0.61), 0.64 (0.53-0.74),
0.54 (0.40, 0.65), 0.59 (0.46-0.69), and 0.37 (0.21-
0.51) for miR-122, HMGB1, apoptosis K18, necrosis
K18, and GLDH activity, respectively. Presentation
and 4-hour back-extrapolated plasma acetaminophen
concentration did not significantly correlate with either
peak ALT activity or peak INR (Fig. 3).
In Patients With a Normal ALT Activity on First
Hospital Presentation, Serum miR-122, HMGB1,
Apoptosis K18, Necrosis K18, and GLDH Activity
Are Higher in Those Who Develop ALI. From our
cohort of 129 acetaminophen overdose patients, we
focused on 98 with an ALT activity <3 ULN with a
median (IQR) value of 21 IU/L (15-29) at first pre-
sentation to determine if the new biomarkers are more
sensitive than ALT. Of these patients, 15 (15%) devel-
oped liver injury (>3 ULN ALT activity; median
peak ALT [IQR] 445 IU/L [224-1187]) during their
hospitalization, whereas 83 (85%) patients did not de-
velop liver injury at any time during the study (<3
ULN ALT activity; median peak ALT [IQR] 19.0 IU/
L [14-25]). First presentation concentration for each
biomarker was significantly higher in patients who
developed ALI than in those who did not (Fig. 4A-E).
Fig. 1. Plasma biomarker values at presentation to the hospital emergency department correlate with peak ALT activity. (A) miR-122, (B) total
HMGB1, (C) apoptosis K18, (D) necrosis K18, and (E) GLDH activity were correlated against peak ALT activity in patients who presented early af-
ter acetaminophen overdose (<24 hours, n ¼ 129).
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The median values (IQR) between the group of
patients who later developed injury and the group that
did not develop toxicity were 9.8 (2.8-96.0) versus
0.17 (0.05-0.43) for miR-122 (P < 0.0001), 2.14
(1.9-4.3) versus 0.41 (0.23-0.63) ng/mL for HMGB1
(P < 0.0001), 298.4 (189.8-648.1) versus 161.1
(133.2-337.4) U/L for apoptosis K18 (P ¼ 0.01),
672.0 (460.1-1098.0) versus 312.1 (237.2-382.0) U/L
for necrosis K18 (P < 0.0001), and 23.00 (16.8-44.8)
versus 13.9 (10.4-18.4) for GLDH activity (P ¼
0.03).
We performed ROC curve analysis on these groups
to provide a robust test of sensitivity and specificity of
our set of markers (Fig. 5A-E). Three of these markers,
miR-122, HMGB1, and necrosis K18 performed with
high AUC values (sensitivity at 90% specificity, 95%
CI, P < 0.0001); 0.93 (0.83, 0.86-1.0, P < 0.0001),
0.97 (0.91, 0.91-1.0, P < 0.0001), and 0.94 (0.90,
0.87-1.0, P < 0.0001), respectively, suggesting that
these markers could provide the greatest separation
between patients with and without ALI at a time when
serum ALT activity was normal. The AUC values (and
sensitivity at 90% specificity, 95% CI) for apoptosis
K18 and GLDH were 0.77 (0.21, 0.63-0.95, P ¼
0.0009) and 0.80 (0.19, 0.68-0.93, P ¼ 0.0003),
respectively. The positive predictive values (negative
predictive values) were 70.6% (97.5%), 85.7%
(97.6%), 70.1% (92.1%), 73.3% (96.3%), and 50.0%
(88.9%) for serum miR-122, HMGB1, apoptosis
K18, necrosis K18, and GLDH, respectively (Fig. 5).
Presentation ALT activity itself was a poor predictor of
the development of acute liver injury, with an AUC of
0.54 (95% CI 0.29-0.71) and a sensitivity of 0.09 at
90% specificity (Fig. 5F).
Circulating miR-122, HMGB1, Apoptosis K18,
Necrosis K18, and GLDH Activity Are Superior to
Serum ALT Activity in Identifying ALI in Patients
Whose First Blood Sample Was Within 8 Hours of
Overdose. From our cohort of 129 acetaminophen
overdose patients, we next focused on 63 with a first
Fig. 2. Plasma biomarker values at presentation to the hospital emergency department correlate with peak INR. (A) miR-122, (B) total
HMGB1, (C) apoptosis K18, (D) necrosis K18, and (E) GLDH activity were correlated against peak INR in patients who presented early after acet-
aminophen overdose (<24 hours, n ¼ 129).
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blood sample taken within 8 hours of drug ingestion
to determine whether the new biomarkers detect early
ALI. Of these patients, 11 (17%) developed liver
injury (>3 ULN serum ALT activity; median peak
ALT [IQR] 487.0 IU/L [266.0-942.0]) during their
hospitalization, whereas 52 (83%) patients did not de-
velop liver injury at any time during the study (serum
ALT activity remained <3 ULN). First presentation
concentration for each biomarker was significantly
higher in patients who developed ALI than those who
did not. The median values (IQR) for patients who
developed ALI and for patients who did not were 3.69
(0.43-96.0) versus 0.21 (0.07-0.81) for miR-122 (P ¼
0.002), 2.14 (1.36-4.33) versus 0.54 (0.34-0.86) ng/
ml for HMGB1 (P < 0.001), 402.7 (129.0-487.0)
versus 159 (126.0-206.0) U/L for apoptosis K18 (P ¼
0.02), 685.0 (435.0-1098.0) versus 328 (242.0-428.0)
U/L for necrosis K18 (P ¼ 0.002), and 33.0 (16.8-
61.0) versus 16.3 (12.0-22.0) for GLDH activity (P ¼
0.03). In contrast, there was no difference in serum
ALT activity; the median values (IQR) for patients
who developed injury and for patients that did not de-
velop ALI were: 21 (12.0-56.0) U/L versus 21 (16.5-
31.5) U/L. We performed an ROC curve analysis (Ta-
ble 2) which demonstrated high predictive perform-
ance of each of the biomarkers to reflect the subse-
quent development of liver injury or not. Consistent
with there being no difference in serum ALT activity
between groups, the ROC curve analysis supported
this finding (Table 2). In addition, the median (IQR)
plasma acetaminophen concentration was not signifi-
cant between patients who did and did not develop
ALI; 177.0 (139.0-208.0) versus 165 (123.0-204.8)
mg/L (P ¼ 0.691). Furthermore, back extrapolation of
the presentation acetaminophen concentration to 4
hours was also not significant between patients who
did and did not develop ALI; 179.0 (165.0-354.0) ver-
sus 269.5 (179.5-351.0) mg/L (P ¼ 0.449). Consist-
ent with there being no difference in plasma acetamin-
ophen concentration between groups, the ROC curve
analysis also supported this finding (Table 2). Table 3
also summarizes the predictive performance for miR-
122, HMGB1, K18, and GLDH quantified from the
first presentation sample to reflect ALI in patients
admitted to the hospital emergency room later than 8
hours following overdose (n ¼ 62). Consistent with
the observations from the <8-hour cohort, these bio-
markers display a strong diagnostic capability com-
pared to ALT activity and plasma acetaminophen con-
centration for patients who develop ALI defined as a
peak ALT activity >3 ULN (n ¼ 20) and those who
do not (n ¼ 42) (Table 3).
Fig. 3. Correlation of admission and 4-hour back-extrapolated plasma acetaminophen concentration with peak ALT and INR. Plasma (A) peak
ALT activity and (B) peak INR were correlated with admission acetaminophen concentration for all patients (n ¼ 129). Plasma (C) peak ALT ac-
tivity and (D) peak INR were correlated with 4-hour back-extrapolated acetaminophen concentration for all patients (n ¼ 129). Correlation coeffi-
cient, Pearson R values, and statistical significance are indicated.
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Discussion
There is an urgent need to identify and validate bio-
markers that show both improved sensitivity and he-
patic specificity to assist the clinical management of
acetaminophen poisoning. Current biomarkers to
assess liver integrity include circulating markers of he-
patocellular death and hepatic function assessed in
combination.5 However, it is well documented that
delayed presentation time, staggered overdose, and a
lack of sensitivity of current clinical chemistry parame-
ters remains a critical impediment to the treatment of
acetaminophen overdose.16-18 Furthermore, there is an
important and unmet need for the development of
improved biomarkers that exhibit higher sensitivity
and specificity for other forms of drug-induced liver
injury (DILI). By building on our previous clinical
investigations,7,8 and the preclinical reports from our
laboratory and from others revealing that these bio-
markers are more sensitive (with respect to time) indi-
cators of changes in hepatic histology than ALT activ-
ity,6,7 we report for the first time that miR-122,
HMGB1, and necrosis K18 represent early and sensi-
tive biomarkers that predict the development of clini-
cal acetaminophen hepatotoxicity.
In acetaminophen overdose patients with established
liver failure, we have shown previously that the circu-
lating level of HMGB1 and necrosis K18 predict
which patients reach the Kings College Criteria (KCC)
and which patients die / require a liver transplant, in
particular the acetylated isoform of HMGB1.9,10
Moreover, our group have shown previously that miR-
122 is 96% higher, on average, in patients meeting
KCC versus patients who did not meet KCC; however,
this did not meet statistical significance (P ¼ 0.15).10
Within our previously published clinical investigations
Fig. 4. Plasma biomarker values are elevated in patients with normal liver function tests who subsequently develop ALI. (A) miR-122, (B)
total HMGB1, (C) apoptosis K18, (D) necrosis K18, (E) GLDH activity, and (F) ALT activity were quantified in plasma from patients who presented
within 24 hours of a acetaminophen overdose and had an ALT activity level within the normal range (<50 IU/L) at presentation (n ¼ 98). Pre-
sentation values for miR-122, total HMGB1, apoptosis K18, necrosis K18, GLDH, and ALT are compared between patients who do not (n ¼ 83)
and do (n ¼ 15) develop ALI, as defined by an ALT activity rising above 3 ULN. Data are given as median (IQR) and statistical significance is
recorded on each figure as required for each biomarker.
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Fig. 5. ROC curve analysis supports the potential for novel biomarkers to predict the development of ALI. ROC analysis was calculated to
determine the potential for plasma (A) miR-122, (B) total HMGB1, (C) apoptosis K18, (D) necrosis K18, (E) GLDH activity, and (F) ALT activity
to predict the development of ALI following presentation <24 hours following acetaminophen overdose. All patients (n ¼ 98) presented with ALT
activity within the normal range (<50 IU/L) and then either subsequently stayed within the normal range (n ¼ 83) or developed ALI as defined
by an ALT activity rising above 3 ULN (n ¼ 15). AUC, statistical significance, and sensitivity (SENS) at 90% specificity is recorded on each fig-
ure as required.
Table 2. Receiver Operator Characteristic (ROC) Curve Analysis Supports the Potential for Novel Biomarkers to Predict the
Development of ALI Within 8 Hours of Acetaminophen Overdose
Biomarker ROC-AUC (95% CI) SENS (95% C.I) PPV NPV P Value
miR-122 0.80 (0.61-1.0) 0.45 (0.29-0.60) 72.7 86.5 0.002
HMGB1 0.83 (0.69-1.0) 0.63 (0.48-0.77) 90.7 86.5 < 0.001
Apoptosis K18 0.73 (0.51-0.96) 0.63 (0.48-0.76) 72.7 96.1 0.02
Necrosis K18 0.80 (0.68-0.97) 0.45 (0.20-0.76) 63.6 86.5 0.002
GLDH 0.71 (0.54-0.89) 0.31 (0.17-0.45) 45.4 88.4 0.03
ALT 0.52 (0.31-0.74) 0.09 (0.02-0.21) 36.3 84.6 0.80
[Acetaminophen] presentation 0.54 (0.38-0.72) 0.18 (0.09-0.30) 27.3 69.2 0.68
[Acetaminophen] 4hr extrapolated 0.57 (0.36-0.78) 0.18 (0.08-0.32) 45.5 28.8 0.44
ROC analysis was calculated to determine the potential for plasma miR-122, total HMGB1, apoptosis K18, necrosis K18, GLDH activity, ALT activity, admission
acetaminophen concentration (above or below 200 mg/L) and 4-hour back-extrapolated acetaminophen concentration (above or below 200 mg/L) to predict the
development of ALI following presentation <8 hours following acetaminophen overdose. All patients (n ¼ 63) presented with ALT activity within the normal range
(<50 IU/L) and then either subsequently stayed within the normal range (n ¼ 52) or developed ALI as defined by an ALT activity rising above 3x ULN (n ¼ 11).
ROC-AUC (area under the curve with 95% CI), sensitivity (SENS with 95% CI) at 90% specificity, positive (PPV) and negative (NPV) predictive value and statistical
significance are given.
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we sought to address the question as to whether or not
these biomarkers could predict the outcome in patients
with established acute liver injury; in the present study
we now present the first data indicating that these bio-
markers hold clinical utility to predict liver injury on
presentation at the hospital emergency department.
Our conclusions are largely based on the observa-
tion and ROC statistical analysis that in this cohort
of acetaminophen overdose patients, when liver func-
tion tests are within the normal range, each of miR-
122, HMGB1, and necrosis K18 strongly predicted
which patients subsequently developed liver injury
and those who did not. Moreover, each biomarker
significantly outperformed plasma acetaminophen
concentrations measured in samples taken at the time
of admittance, and 4-hour back-extrapolated acet-
aminophen determinations, for the prediction of the
subsequent development of ALI. All the patients
within our cohort received AC after the first blood
sample was taken and no significant kidney injury
was detected. The serum levels of each of the bio-
markers investigated were not significantly elevated in
patients who did not develop liver injury compared
to healthy volunteers from our previous study.9,10
Immunohistochemistry data obtained from a mouse
model of acetaminophen-induced ALI indicates that
miR-122 is hepatocyte-specific and is lost progres-
sively from necrotic areas of the liver during acet-
aminophen-induced liver injury (data not shown).
The fact that miR-122 is greatly enriched in hepato-
cytes14 provides a significant advance in the develop-
ment of novel biomarkers to identify and stratify acet-
aminophen hepatotoxicity early.
During the comparison of the presentation bio-
marker values between cohorts that did and did not
subsequently develop liver injury, the potential of both
GLDH and apoptosis K18 to reflect the development
of liver injury was observed with less significance than
miR-122, HMGB1, and necrosis K18. The induction
of apoptosis by acetaminophen has been shown in ani-
mal models and also clinically during endstage acet-
aminophen hepatotoxicity by histology and the
enzyme-linked immunosorbent assay (ELISA) detec-
tion of caspase-cleaved K18.19,20 However, necrotic
cell death predominates and is a major factor in the
development of acetaminophen-induced acute liver
failure. The occurrence of apoptosis during acetamino-
phen hepatotoxicity is controversial. Studies reporting
the identification of acetaminophen-induced apoptosis
confirm that apoptosis is a minor event both clinically
and in vivo and pan-caspase inhibitors do not protect
against acetaminophen-induced liver injury.6,9 Rapid
mitochondrial dysfunction is closely linked to hepato-
cyte necrosis and has been postulated as a reason for
the lack of apoptosis during acetaminophen hepatotox-
icity.21 Furthermore, using GLDH as a biomarker of
mitochondrial dysfunction, recent reports have shown
that GLDH activity closely associates with ALT activity
during clinical acetaminophen hepatotoxicity,8 a find-
ing replicated in our cohort. Therefore, the variable
and minimal involvement of apoptosis during clinical
and preclinical acetaminophen hepatotoxicity and the
fact that GLDH activity is closely associated with ALT
activity could, in part, explain the reduced sensitivity
of these two biomarkers, compared to the others inves-
tigated here, to predict the development of ALI in a
clinical setting.
Although the data presented here provide evidence
that miR-122, HMGB1, and necrosis K18 represent
sensitive and early biomarkers of clinical acetamino-
phen hepatotoxicity, without a tissue biopsy reflecting
the actual degree of organ damage the observed quan-
tification of these biomarkers could, in theory, over-
state the degree of cell death. However, our data are
Table 3. Receiver Operator Characteristic (ROC) Curve Analysis Supports the Potential for Novel Biomarkers to Predict the
Development of ALI in Patients Presenting Later Than 8 Hours After an Acetaminophen Overdose
Biomarker ROC-AUC (95% CI) SENS PPV NPV P Value
miR-122 0.98 (0.95-1.0) 0.95 (0.83-0.99) 100.0 95.2 < 0.0001
HMGB1 0.99 (0.96-1.0) 0.91 (0.77-0.99) 100.0 90.4 < 0.0001
Apoptosis K18 0.91 (0.84-0.99) 0.65 (0.48-0.78) 80.0 90.4 < 0.0001
Necrosis K18 0.95 (0.90-1.0) 0.92 (0.81-0.98) 95.0 90.4 < 0.0001
GLDH 0.84 (0.71-0.97) 0.69 (0.52-0.82) 85.0 90.4 < 0.0001
ALT 0.96 (0.92-1.0) 0.76 (0.61-0.88) 80.0 90.4 < 0.0001
[Acetaminophen] presentation 0.60 (0.46-0.76) 0.28 (0.15-0.44) 0.0 92.8 0.1968
[Acetaminophen] 4hr extrapolated 0.54 (0.37-0.71) 0.11 (0.03-0.25) 85.0 30.9 0.6279
ROC analysis was calculated to determine the potential for plasma miR-122, total HMGB1, apoptosis K18, necrosis K18, GLDH activity, ALT activity, admission
acetaminophen concentration (above or below 200 mg/L) and 4-hour back-extrapolated acetaminophen concentration (above or below 200 mg/L) to predict the
development of ALI following presentation >8 hours following acetaminophen overdose. All patients (n ¼ 62) either developed liver injury (peak ALT activity >150
U/L, n ¼ 20) or did not (n ¼ 42). ROC-AUC (area under the curve with 95% CI), sensitivity (SENS with 95% CI) at 90% specificity, positive (PPV) and negative
(NPV) predictive value and statistical significance are given.
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consistent with those obtained in preclinical models,
where quantitative circulating levels of a particular bio-
marker can be directly related to changes (or a lack of
a change) in hepatic histology over time,6,7 and the
finding that these biomarkers can report on the mech-
anistic basis of other DILIs in patient cohorts.15 Qual-
ification is a common challenge for potential new bio-
markers in man and it is important to note that ALT
itself has never been fully qualified against human his-
tology for drug-induced hepatotoxicity. Furthermore,
the potential importance of the findings presented here
is underpinned by the relatively heterogeneous nature
of acetaminophen overdose cohort samples (particu-
larly with respect to the amount of acetaminophen
ingested and the time of presentation). We therefore
believe that our data add to the growing body of evi-
dence to support the ongoing clinical qualification of
these markers of liver injury.
Within this continually evolving field, despite our
evidence highlighting the sensitivity of these bio-
markers in early overdose patients (<24 hours), little
is still known regarding their kinetics in blood com-
pared with ALT activity and their prognostic utility at
later timepoints. However, our previously published
clinical studies in the setting of acetaminophen over-
dose and heparin-induced liver injury reveal that these
biomarkers appear to have a shorter half-life than ALT
activity (24 hours compared to 48 hours) and return
to baseline levels more rapidly than ALT activity.9,10,15
The utility of these markers at timepoints later than
48 hours is also highlighted in these studies, given
their prognostic utility in late-presenting patients with
established liver injury.
In summary, at first presentation to the hospital,
miR-122, HMGB1, and necrosis K18 are more
sensitive than ALT at identifying acetaminophen-
induced acute liver injury. They have the potential
to refine patient care in a number of ways. Future
clinical trials of new therapeutic strategies could
include one or more of these markers in the
patient inclusion criteria with the objective of tar-
geting new therapies or management pathways in
lower or higher risk patients. If such trials were
successful, more individualized treatment would be
possible at the hospital ‘‘front door,’’ as is already
the case with the management of acute coronary
syndromes (being stratified by sensitive cardiac bio-
markers such as troponin). Currently, patients who
have taken a single acetaminophen overdose, who
present late to the hospital, can only have liver
injury confidently excluded if their liver function
tests are normal around 24-36 hours after drug
ingestion. The new biomarkers described in this ar-
ticle may allow earlier exclusion of injury, which
would have an impact on hospital bed occupancy
and avoid adverse acetylcysteine reactions by reduc-
ing unnecessary treatment. Patients with a timed
blood acetaminophen concentration below the at-
risk line on the treatment nomogram are usually
not treated with acetylcysteine. Measurement of
more sensitive markers, such as miR-122 and
HMGB1 alongside ALT in these patients may
increase physician confidence in discharging the
patient from the hospital, although this requires a
specific study in this group, as all the patients in
the present study received treatment. Despite
patients in the present study developing ALI, none
reached the KCC for transplantation, received a
liver transplant or died because22 70% of our
cohort was admitted to the hospital within the
time frame required where prompt AC treatment is
expected to be near 100% effective. It remains to
be determined if the new biomarkers can predict
these important clinical outcomes at first presenta-
tion to the hospital.
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